RxDoctor Payments Data

Jazmine Alanis, PA

Physician Assistant · Austin, TXNPI 1003556069

Payments from drug & device makers

$6,581in general payments, 2019–2025

Across 350 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$820
  • Alkermes, Inc.$687
  • Otsuka America Pharmaceutical, Inc.$627
  • Corium, LLC$570
  • Teva Pharmaceuticals USA, Inc.$499
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$490
  • plus $3K from 18 others

What the payments were for

  • Food & beverage$6,30996%
  • Education$2724%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,581 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$5,926
Medicare patients
33
Services billed
79

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate41$123,102
IngrezzaValbenazine Tosylate17$110,801
RexultiBrexpiprazole11$15,077
Aripiprazole47$12,010
Lurasidone Hcl18$6,626
Paliperidone ErPaliperidone14$3,810
Divalproex Sodium ErDivalproex Sodium11$1,290
Bupropion XlBupropion Hcl67$1,129
Hydroxyzine Hcl49$1,018
Quetiapine Fumarate55$938
Gabapentin56$904
Olanzapine47$759
Duloxetine Hcl65$601
Buspirone Hcl52$535
Prazosin Hcl38$484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$149$123,10241 claims
Neurocrine Biosciences, Inc.Ingrezza$371$110,80117 claims
Otsuka America Pharmaceutical, Inc.Rexulti$627$15,07711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →